Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "GMS-pathway control state"

From Bioblast
Line 7: Line 7:
Transaminase catalyzes the reaction from oxaloacetate to 2-oxoglutarate, which then establishes a cycle without generation of citrate. OXPHOS is higher with GS (CI&II) compared to GM (CI) or SRot (CII). This documents an additive effect of convergent CI&II electron flow to the Q-junction, with consistent results obtained with permeabilized muscle fibres and isolated mitochondria (Gnaiger 2009).
Transaminase catalyzes the reaction from oxaloacetate to 2-oxoglutarate, which then establishes a cycle without generation of citrate. OXPHOS is higher with GS (CI&II) compared to GM (CI) or SRot (CII). This documents an additive effect of convergent CI&II electron flow to the Q-junction, with consistent results obtained with permeabilized muscle fibres and isolated mitochondria (Gnaiger 2009).
|info=[[Gnaiger 2014 MitoPathways |Gnaiger 2014 MitoPathways - Chapter 5.5]]
|info=[[Gnaiger 2014 MitoPathways |Gnaiger 2014 MitoPathways - Chapter 5.5]]
[[File:GMS.jpg|right|400px|GMS]]
}}
}}
{{MitoPedia concepts}}
{{MitoPedia concepts
{{MitoPedia methods}}
|mitopedia concept=SUIT state
{{MitoPedia O2k and high-resolution respirometry
|mitopedia O2k and high-resolution respirometry=SUIT state
}}
}}
{{MitoPedia topics}}
{{MitoPedia topics}}
== GMS(L) ==
== GMS<sub>''L''</sub> ==
GMS pathway in the LEAK state can be evaluated in the following SUIT protocols:


== GMS<sub>''P''</sub>==
GMS pathway in the OXPHOS state can be evaluated in the following SUIT protocols:
:::*[[SUIT-011]]


== GMS(P) ==
== GMS<sub>''E''</sub>==
Β 
GMS pathway in the ET state can be evaluated in the following SUIT protocols:
Β 
:::*[[SUIT-011]]
== GMS(E) ==
Β 


== Discussion ==
== Discussion ==

Revision as of 16:23, 22 January 2019


high-resolution terminology - matching measurements at high-resolution


GMS-pathway control state

Description

GMS

GMS: Glutamate & Malate & Succinate.

MitoPathway control: CI&II

Transaminase catalyzes the reaction from oxaloacetate to 2-oxoglutarate, which then establishes a cycle without generation of citrate. OXPHOS is higher with GS (CI&II) compared to GM (CI) or SRot (CII). This documents an additive effect of convergent CI&II electron flow to the Q-junction, with consistent results obtained with permeabilized muscle fibres and isolated mitochondria (Gnaiger 2009).

Abbreviation: GMS

Reference: Gnaiger 2014 MitoPathways - Chapter 5.5

GMS


MitoPedia concepts: SUIT state 



GMSL

GMS pathway in the LEAK state can be evaluated in the following SUIT protocols:

GMSP

GMS pathway in the OXPHOS state can be evaluated in the following SUIT protocols:

GMSE

GMS pathway in the ET state can be evaluated in the following SUIT protocols:

Discussion

In human skeletal muscle mitochondria (25 Β°C), Rasmussen and Rasmussen (2000) obtained CI/CI&II flux ratios of 0.7 (0.6) for OXPHOS (or ETS) with glutamate&malate (8+4 mM) and glutamate&succinate (4+8 mM), and CII/CI&II flux ratios of 0.8 (0.6) for OXPHOS (or ETS). The GMP/GMSE and S(Rot)E/GMSE flux control ratios are 0.50 and 0.55 in human vastus lateralis (Pesta et al 2011). Due to the lower H+/O2 stoichiometry in succinate respiration compared to CI-linked respiration (two versus three coupling sites), the CI/CI&II ratio is lower for LEAK respiration (0.3 to 0.4; Garait et al 2005) compared to OXPHOS capacity. In human skeletal muscle, the phosphorylation system is more limiting at the highest OXPHOS activity with glutamate&succinate, at a P/E ratio (GSP/GSE) of 0.69 versus 0.80 with glutamate&malate (Rasmussen and Rasmussen 2000). Failure of obtaining a further stimulation of coupled OXPHOS in human skeletal muscle mitochondria with GMS by uncoupling (Kunz et al 2000) can be explained by the high FCCP concentration applied (10 Β΅M) which is known to inhibit respiration (Steinlechner-Maran et al 1996). In mouse skeletal muscle, however, the P/E ratio is actually 1.0 (Aragones et al 2008), which contrasts with the significant limitation of OXPHOS capacity by the phosphorylation system in humans